Silence Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Silence Therapeutics es Craig Tooman , nombrado en Feb 2022, tiene una permanencia de 2.75 años. compensación anual total es £7.30M, compuesta por 6.5% salario y 93.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.024% de las acciones de la empresa, por valor de $80.48K. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 4.8 años, respectivamente.

Información clave

Craig Tooman

Chief Executive Officer (CEO)

UK£7.3m

Compensación total

Porcentaje del salario del CEO	6.5%
Permanencia del CEO	2.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Craig Tooman en comparación con los beneficios de Silence Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-UK£59m
Jun 30 2024	n/a	n/a	-UK£40m
Mar 31 2024	n/a	n/a	-UK£35m
Dec 31 2023	UK£7m	UK£473k	-UK£43m
Sep 30 2023	n/a	n/a	-UK£43m
Jun 30 2023	n/a	n/a	-UK£41m
Mar 31 2023	n/a	n/a	-UK£43m
Dec 31 2022	UK£6m	UK£461k	-UK£40m
Sep 30 2022	n/a	n/a	-UK£36m
Jun 30 2022	n/a	n/a	-UK£39m
Mar 31 2022	n/a	n/a	-UK£39m
Dec 31 2021	UK£2m	UK£334k	-UK£39m

Compensación vs. Mercado: La compensación total de Craig($USD9.15M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.16M).

Compensación vs. Ingresos: La compensación de Craig ha aumentado mientras la empresa no es rentable.

CEO

Craig Tooman (59 yo)

2.8yrs

Permanencia

UK£7,298,000

Compensación

Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Tooman	President	2.8yrs	UK£7.30m	0.024% $ 80.5k
Rhonda Hellums	Executive VP	2.8yrs	UK£2.50m	0.0011% $ 3.6k
Steven Romano	Executive VP and Chief Research & Development Officer	1.6yrs	UK£1.82m	0.0092% $ 31.2k
Marie Lindholm	Chief Scientific Officer	less than a year	sin datos	sin datos
Gem Hopkins	Head of IR & Corporate Communications	no data	sin datos	sin datos
Gianine Esposito	Chief Human Resources Officer	less than a year	sin datos	sin datos
Barbara Ruskin	Senior VP and Chief Intellectual Property & Innovation Officer	2.2yrs	sin datos	sin datos
Eric Floyd	Senior Vice President of Regulatory Affairs & Quality Assurance	4.3yrs	sin datos	sin datos
J.P. Gabriel	Chief Technical Operations Officer	2yrs	sin datos	sin datos
Curtis Rambaran	Chief Medical Officer	no data	sin datos	sin datos

2.1yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SLNC.F se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Tooman	President	2.8yrs	UK£7.30m	0.024% $ 80.5k
David Lemus	Independent Non-Executive Director	6.4yrs	UK£184.00k	0.0053% $ 18.1k
Gordon Duff	Chairman of Scientific Advisory Board	4.8yrs	sin datos	sin datos
Michael Davidson	Independent Non-Executive Director	3.8yrs	UK£178.00k	0.0092% $ 31.2k
Iain Ross	Independent Chairman of the Board	5.6yrs	UK£402.00k	0.078% $ 264.2k
John Porter	Member of Scientific Advisory Board	4.8yrs	sin datos	sin datos
James Ede-Golightly	Independent Non-Executive Director	5.6yrs	UK£182.00k	0.011% $ 36.1k
Henry Ginsberg	Member of Scientific Advisory Board	4.8yrs	sin datos	sin datos
Annemieke Aartsma-Rus	Member of Scientific Advisory Board	4.8yrs	sin datos	sin datos
John Whittaker	Member of Scientific Advisory Board	4.4yrs	sin datos	sin datos
Jenny Sims	Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos
Tom Brown	Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos

4.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de SLNC.F se considera experimentada (4.8 años de antigüedad promedio).

Silence Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

Silence Therapeutics plc Announces Executive Changes

Recent updates

Silence Therapeutics plc Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)

Silence Therapeutics plc to Report Q4, 2023 Results on Mar 13, 2024

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics plc Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics plc to Report Q4, 2021 Results on Mar 17, 2022

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volunteer Study

Silence Therapeutics Updates on AIM Delisting

Silence Therapeutics plc announced that it has received $40 million in funding from AstraZeneca PLC

Silence Therapeutics plc Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

Silence Therapeutics plc to Report Fiscal Year 2020 Results on Mar 30, 2021

Silence Therapeutics plc & Mallinckrodt plc Initiate Work on 3Rd Target

Silence Therapeutics plc announced that it has received $45.499905 million in funding from a group of investors

Silence Therapeutics plc Initiates Dosing in Phase 1 Clinical Trial of Sln360 for Cardiovascular Disease Due to High Lipoprotein(A)

Silence Therapeutics Appoints Michael H. Davidson to Board of Directors

Silence Therapeutics Appoints Craig Tooman as CFO

Silence Therapeutics plc Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) At American Heart Association 2020

Silence Therapeutics plc Appoints Marie Wikström Lindholm as Senior Vice President, Molecular Design and Member of the Silence Executive Leadership Team

Silence Therapeutics plc Announces Rob Quinn, the Current CFO Will Leave the Company in January 2021

Silence Therapeutics Appoints Mark Rothera as Chief Executive Officer

Silence Therapeutics plc has completed a Follow-on Equity Offering in the amount of $311.826401 million.

Silence Therapeutics plc to Report First Half, 2020 Results on Sep 14, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad